Table 1 Baseline characteristics in the SARS-CoV-2 infection and first SARS-CoV-2 negative test cohorts, by database
From: The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis
SIDIAP | CPRD | |||
|---|---|---|---|---|
SARS-CoV-2 infection | First SARS-CoV-2 negative test | SARS-CoV-2 infection | First SARS-CoV-2 negative test | |
N | 448,361 | 1,644,166 | 480,901 | 1,508,585 |
SARS-CoV-2 PCR test (%) | 233,281 (52.0) | 1,644,166 (100.0) | 338,504 (70.4) | 1,508,585 (100.0) |
Test date period (%) | ||||
Sep–Dec 2020 | 127,419 (28.4) | 700,640 (42.6) | 211,657 (44.0) | 914,008 (60.6) |
Jan–Apr 2021 | 137,539 (30.7) | 527,588 (32.1) | 186,027 (38.7) | 571,401 (37.9) |
May–Aug 2021 | 159,904 (35.7) | 289,618 (17.6) | 74,405 (15.5) | 23,040 (1.5) |
Sep–Dec 2021 | 23,499 (5.2) | 126,320 (7.7) | 8812 (1.8) | 136 (0.0) |
Wave (%) | ||||
Wild | 106,231 (23.7) | 601,101 (36.6) | 148,901 (31.0) | 734,616 (48.7) |
Alpha | 165,159 (36.8) | 667,662 (40.6) | 252,093 (52.4) | 768,109 (50.9) |
Delta | 176,971 (39.5) | 375,403 (22.8) | 79,907 (16.6) | 5860 (0.4) |
Days of follow-up (median [IQR]) | 342 [249,365] | 365 [276, 365] | 364 [300, 365] | 365 [334, 365] |
Age (median [IQR]) | 42 [29, 56] | 47 [34, 62] | 41 [29, 54] | 41 [30, 55] |
Age, categories (%) | ||||
≤34 | 159,888 (35.7) | 423,729 (25.8) | 176,631 (36.7) | 529,987 (35.1) |
35–49 | 132,947 (29.7) | 472,047 (28.7) | 139,975 (29.1) | 457,006 (30.3) |
50–64 | 90,924 (20.3) | 390,178 (23.7) | 112,104 (23.3) | 360,586 (23.9) |
65–79 | 41,208 (9.2) | 258,997 (15.8) | 37,204 (7.7) | 127,153 (8.4) |
≥80 | 23,394 (5.2) | 99,215 (6.0) | 14,987 (3.1) | 33,853 (2.2) |
Sex, male (%) | 195,901 (43.7) | 771,431 (46.9) | 218,169 (45.4) | 662,853 (43.9) |
Vaccination status (%) | ||||
Not vaccinated | 80,053 (17.9) | 221,018 (13.4) | 75,583 (15.7) | 165,818 (11.0) |
One dose | 149,014 (33.2) | 242,323 (14.7) | 71,496 (14.9) | 110,386 (7.3) |
Two doses | 132,782 (29.6) | 475,664 (28.9) | 143,346 (29.8) | 475,537 (31.5) |
Three or more (booster) doses | 86,512 (19.3) | 705,161 (42.9) | 190,476 (39.6) | 756,844 (50.2) |
Comorbidities (%) | ||||
Asthma | 34,729 (7.7) | 124,092 (7.5) | 80,565 (16.8) | 253,906 (16.8) |
Autoimmune disease | 8426 (1.9) | 35,035 (2.1) | 12,776 (2.7) | 40,531 (2.7) |
COPD | 11,860 (2.6) | 61,399 (3.7) | 9463 (2.0) | 26,131 (1.7) |
Dementia | 8377 (1.9) | 17,073 (1.0) | 5292 (1.1) | 13,666 (0.9) |
Diabetes | 36,609 (8.2) | 156,220 (9.5) | 35,636 (7.4) | 95,640 (6.3) |
Heart disease | 49,726 (11.1) | 219,520 (13.4) | 34,929 (7.3) | 99,275 (6.6) |
Cancer | 29,106 (6.5) | 142,116 (8.6) | 21,259 (4.4) | 69,447 (4.6) |
Hypertension | 76,227 (17.0) | 360,097 (21.9) | 66,130 (13.8) | 194,132 (12.9) |
Renal impairment | 18,779 (4.2) | 83,165 (5.1) | 20,135 (4.2) | 51,474 (3.4) |
